3 sonuçtan 1 ile 3 arası

Konu: Yeni Çıkan Antidepresanlar Listesi

  1. #1
    Guest

    Standart Yeni Çıkan Antidepresanlar Listesi

    Çoğu yerde yasal uyuşturucu olarak geçen ve kimileri için yaşama nedeni olan antidepresanların dünyasında son gelişmelere bakacağız hep beraber. sırayla size en son çıkan ve daha ülkemizde bulunmayan çoğunun isminden psikiatristlerin bile haberi olmayan bu ilaçları tanıyacağız

  2. #2
    Guest

    Standart

    Desvenlafaxine (Pristiq): Newest antidepressant. Similar to venlafaxine.

    Desvenlafaxine (Pristiq): En son çıkan antidepresanımız. venlafaxine ile benzerlik gösteriyor.

    işte şöle bişey:

    Formülü de böle:

    Reklamı da böle:

    tabi bizde ilaç reklamı yasak. neyse

    Desvenlafaxine

    Desvenlafaxine
    Systematic (IUPAC) name
    4-[2-dimethylamino-1-(1-hydroxycyclohexyl)
    ethyl]phenol
    Identifiers
    CAS number 93413-62-8
    ATC code N06AX23
    PubChem 125017
    Chemical data
    Formula C16H25NO2
    Mol. mass 263.375 g/mol
    Synonyms O-desmethylvenlafaxine
    Norvenlafaxine
    Pharmacokinetic data
    Bioavailability 80%
    Protein binding Low (30%)
    Metabolism CYP3A4, (CYP2D6 is not involved)
    Half life 11 hours
    Excretion 45% excreted unchanged in urine
    Therapeutic considerations
    Licence data



    Desvenlafaxine succinate, marketed under the name Pristiq, is an antidepressant of the serotonin-norepinephrine reuptake inhibitor class from Wyeth. It is a metabolite of venlafaxine (Effexor). Although Wyeth touts the notion that Pristiq is being targeted as the first non-hormonal based treatment for menopause[1], in fact, the anticonvulsant medication gabapentin already owns this distinction.

    Resmi Websitesi: http://www.pristiq.com/



    Medication Guide for patients

    Prospektüs

    Approval status

    Wyeth announced on 23 January 2007 that it received an "approvable" letter from the Food and Drug Administration for desvenlafaxine. Final approval to sell the drug was contingent on a number of things, including:

    * a satisfactory FDA inspection of Wyeth's Guayama, Puerto Rico facility, where the drug is to be manufactured;
    * several post-marketing commitments;
    * clarity by Wyeth around the company's product education plan for physicians and patients;
    * approval of desvenlafaxine's proprietary name, Pristiq.[2]

    The FDA approved the drug for antidepressant use in February 2008, and will be available in US pharmacies in May 2008.[3]

    On February 4, 2009, Health Canada approved use of desvenlafaxine for treatment of depression in Canada.[4] As of March 2009, Pristiq is not yet available in Canadian pharmacies.

    Executive Summary

    Desvenlafaxine succinate extended release tablets, (hereafter referred to as desvenlafaxine), is a norepinephrine/serotonin reuptake inhibitor. Desvenlafaxine is a synthetic form of a known active metabolite of venlafaxine.

    Current Standard of Therapy

    For Major Depressive Disorder (MDD), there is no single, gold standard treatment modality. The approach to treatment depends on patient preference, compliance, and practitioner assessment. For mild to severe depression without psychoses or suicidal ideation, psychotherapy, medications, or both are first line treatments. The specific pharmacotherapy choice depends on patient’s past experience, acceptance, and specific complaints (insomnia, somnolence, pain, etc.).[5] Some common first line pharmacological agents include SSRI, TCAs, DNRI, SNRI.[5]

    Objective assessment of patient’s initial status and progress involved one of several surveys including AMSIT Mental Status Exam, Hamilton Depression Scale (HAM-D17), and a Major Depression Inventory. Adequate response to therapy is defined as a >=50% reduction in Depression scores. Stages of Major Depressive Episode Treatment include Acute (12wks), Continuation (4-9 months) and Maintenance Phases. Typical therapy lasts not only for the acute phase, but is maintained for an additional 16-36 weeks during the continuation phase. Only after the continuation phase is the discontinuation of therapy considered.[5][6]

    Side Effects

    Side effect profiles were consistent for all three studies evaluated, with nausea being the most profound and prevalent. Although rates varied substantially from study to study, nausea was consistently the most common complaint (30-50% vs placebo 9-11%) and the most common reason for discontinuation.[7][8][9] Suicidal ideation was monitored and was determined to be significant in 1-2 patients in each study.[7][8][9] The most commonly observed adverse reactions in Pristiq-treated MDD patients in short-term fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, priaprism, night terrors, anxiety, and specific male sexual function disorders.[10]. These side effect patterns are consistent with other SNRIs venlafaxine and duloxetine.[11][12] Relative rates are not available, as there were no head to head studies.

    Clinical Efficacy

    Internal Validity


    In published phase III Trials, desvenlafaxine was compared only to placebo. In these trials, primary endpoints were powered to measure a reduction in depression (HAM-D17) scores[7][8][9] not the standard response measure of >=50% reduction in depression scores.[6]

    Response scores were secondary measures, which the studies may or may not have been powered to address. These trials showed dose-erratic reductions in HAM-D17 scores, which undermined the results. Response rates varied from 43-60%, which is lower than most current antidepressants, which have a 60-70% response rate.[6] Remission rates of 23-37% for desvenlafaxine are also lower than other antidepressant rates of 30-40%. Of course, generalizations of this nature cannot be made without careful statistical testing, which was beyond the scope of this project.

    Treatment duration for the three reviewed trials seemed inadequate, given the staging of MDD. MDD acute phase lasts 12 weeks, while all three reviewed studies only treated patients for 8 weeks.[5][6] Although it may not be practical or required to continue therapy for an entire year during a study, it is difficult to determine if desvenlafaxine is an appropriate therapy without these data.

    External Validity

    There may be some differences in efficacy across ethnic backgrounds. One study, with three different dose strengths, showed efficacy in the 100mg and 400mg doses, but no efficacy in the 200mg dose. This group had a notably higher proportion of blacks and Hispanics than the other two active groups. The only other study which listed ethnic distributions had a notably higher proportion of blacks and Hispanics in the placebo group vs. the active group. Although kinetic studies have indicated there are no known active metabolites for desvenlafaxine, the possibility of ethnic variations in response cannot be ruled out.[13]

    Notes

    1. ^ Wyeth (2007-07-24). Wyeth Receives Approvable Letter From FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated With Menopause. Press release. http://www.wyeth.com/news?nav=displa...276550318.html. Retrieved on 2007-07-31.
    2. ^ Wyeth Receives Approvable Letter From FDA For Pristiq (Desvenlafaxine Succinate) For The Treatment Of Major Depressive Disorder. Press release. 2007-01-23. http://www.biospace.com/news_story.a...D=43424&full=1. Retrieved on 2007-04-04.
    3. ^ Wyeth (2008-02-29). FDA Approves Pristiq. Press release. http://www.wyeth.com/news?nav=displa...331198948.html. Retrieved on 2008-02-29.
    4. ^ Health Canada Notice of Compliance - Pristiq. February 4, 2009, retrieved on March 9, 2009.
    5. ^ a b c d Karasu, TB; Gelenberg, A; Meriam, A; Wang, P. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition. American Psychiatric Association. doi:10.1176/appi.books.9780890423363.48690. http://www.psychiatryonline.com/content.aspx?aid=48690. Retrieved on 2008-04-22.
    6. ^ a b c d Koda-Kimble, Mary Anne; Young, Lloyd Lee; Kradjan Wayne A, Guglielmo, B. Joseph; Alldredge, Brian K. (June 2004). Applied Therapeutics: The Clinical Use of Drugs. Lippincott Williams & Wilkins. ISBN 978-0781748452.
    7. ^ a b c DeMartinis, NA; Yeung, PP; Entsuah, R; Manley, AL (2007). "A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder". J Clin Psychiatry 68 (5): 677-88.
    8. ^ a b c Liebowitz, MR; Yeung, PP; Entsuah, R.. "A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder". J Clin Psychiatry 68 (11): 1663-72.
    9. ^ a b c Septien-Velez, L; Pitrosky, B; Padmanabhan, SK; Germain, JM; Tourian, KA (2007). "A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder". Int Clin Psychopharmacol 22 (6): 338-47.
    10. ^ Pristiq Package Insert
    11. ^ Effexor XR package insert. Philadelphia, PA; Wyeth, 2/2008
    12. ^ Cymbalta package insert. Indianapolis, IN; Eli Lilly 12/2007
    13. ^ Desvenlafaxine package insert. Philadelphia, PA; Wyeth; 2/2008



    Systematic (IUPAC) name
    4-[2-dimethylamino-1-(1-hydroxycyclohexyl)
    ethyl]phenol
    Identifiers
    CAS number 93413-62-8
    ATC code N06AX23
    PubChem 125017
    Chemical data
    Formula C16H25NO2
    Mol. mass 263.375 g/mol
    Synonyms O-desmethylvenlafaxine
    Norvenlafaxine
    Pharmacokinetic data
    Bioavailability 80%
    Protein binding Low (30%)
    Metabolism CYP3A4, (CYP2D6 is not involved)
    Half life 11 hours
    Excretion 45% excreted unchanged in urine
    Therapeutic considerations
    Licence data

    US FDA:link
    Pregnancy cat.

    C(US)
    Legal status

    ℞-only(US)
    Routes Oral




  3. #3
    Guest

    Standart

    şimdilik bu kadar yeter sıkıldım,

    önümüzdeki günlerde aşağıdaki ilaçları anlatacağım


    # Duloxetine (Cymbalta): Dosing 40 mg two X daily or 60 mg once daily.

    # Milnacipran: (Ixel): Serotonin/norepinhephrine reuptake inhibitor. Manufactured in France by Pierre Fabre.

    # Venlafaxine (Effexor): Also used to treat generalized anxiety disorder and social anxiety disorder. Dose should be titrated upward starting at 37.5 mg X one week. Maximum dose 225 mg in XL form. Blood pressure should be monitored as this medication can increase it.

Benzer Konular

  1. Fobi Listesi
    By dertli biri in forum Paylaşım Köşesi
    Cevaplar: 14
    Son Mesaj: 16-04-2013, 12:18 AM
  2. Anksiyeteye iyi gelen yiyeceklerin listesi ve negatif etki yapan yiyeceklerin listesi
    By defiance in forum Genel Kaygı / Anksiyete Bozuklukları
    Cevaplar: 0
    Son Mesaj: 05-02-2012, 09:19 PM
  3. Psikiyatrlık Hastaların Listesi - DSM 4 Listesi
    By Antropolog in forum Hikayeler & Yazılar
    Cevaplar: 2
    Son Mesaj: 28-03-2011, 12:46 PM
  4. Cevaplar: 38
    Son Mesaj: 01-01-2011, 02:00 AM
  5. Takıntılar Listesi
    By iyimserimben in forum Takıntılarımız ( Obsesyon & Kompulsiyonlar )
    Cevaplar: 54
    Son Mesaj: 12-05-2010, 03:29 AM

Bu Konudaki Etiketler

Yer imleri

Yetkileriniz

  • Konu Acma Yetkiniz Yok
  • Cevap Yazma Yetkiniz Yok
  • Eklenti Yükleme Yetkiniz Yok
  • Mesajınızı Değiştirme Yetkiniz Yok
  •